Nippon Shinyaku Co., Ltd. (NPPNY)
| Market Cap | 1.72B |
| Revenue (ttm) | 997.63M |
| Net Income (ttm) | 193.37M |
| Shares Out | n/a |
| EPS (ttm) | 2.87 |
| PE Ratio | 8.89 |
| Forward PE | n/a |
| Dividend | 0.85 (13.03%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 272 |
| Average Volume | 1,066 |
| Open | 6.50 |
| Previous Close | 6.50 |
| Day's Range | 5.56 - 6.50 |
| 52-Week Range | 4.90 - 7.26 |
| Beta | -0.24 |
| RSI | 61.28 |
| Earnings Date | May 8, 2025 |
About Nippon Shinyaku
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. Its Pharmaceuticals Business segment offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases. The company’s Functional Food Business segments provides health food ingredients, preservatives, protein preparations, and sports and supplements. The company in the Strategic Partnership with Nippon Shiny... [Read more]
Full Company ProfileFinancial Performance
In 2023, Nippon Shinyaku's revenue was 148.26 billion, an increase of 2.83% compared to the previous year's 144.18 billion. Earnings were 25.85 billion, an increase of 13.32%.
Financial numbers in JPY Financial StatementsNews
Regenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121
REGENXBIO partners with Nippon Shinyaku for MPS therapies
Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Shares of KB Home (NYSE: KBH) rose sharply in today's pre-market trading after the company posted better-than-expected fourth-quarter financial results. KB Home reported fourth-quarter revenue of $2 ...
Week In Review: Nippon Shinyaku Signs $735m Deal For DMD Therapy
Japan’s Nippon Shinyaku will acquire European rights for a Duchenne muscular dystrophy disease therapy developed by Capricor Therapeutics of San Diego. Read more here.
Capricor Therapeutics partners with Nippon Shinyaku for European commercialization of Deramiocel
Capricor Therapeutics partners with Nippon Shinyaku for European distribution of Duchenne muscular dystrophy treatment, deramiocel.
EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm
Tuesday, Capricor Therapeutics Inc (NASDAQ: CAPR) entered into a binding term sheet with Nippon Shinyaku Co., Ltd. , a Japanese pharmaceutical company, for the commercialization and distribution in E...